Modality
ERT
MOA
USP1i
Target
SMN2
Pathway
mTOR
LGSHeart FailureRSV
Development Pipeline
Preclinical
Mar 2019
→ Jan 2029
PreclinicalCurrent
NCT03479025
2,518 pts·RSV
2019-03→2029-01·Completed
2,518 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-032.8y awayInterim· RSV
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Preclinical
Complet…
Catalysts
Interim
2029-01-03 · 2.8y away
RSV
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03479025 | Preclinical | RSV | Completed | 2518 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |